Compare ALC & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALC | ONC |
|---|---|---|
| Founded | 1945 | 2010 |
| Country | Switzerland | Switzerland |
| Employees | N/A | 12000 |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.9B | 31.4B |
| IPO Year | 2002 | N/A |
| Metric | ALC | ONC |
|---|---|---|
| Price | $66.04 | $291.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | $89.38 | ★ $385.10 |
| AVG Volume (30 Days) | ★ 2.1M | 201.5K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.99 | $723.76 |
| Revenue Next Year | $6.38 | $15.04 |
| P/E Ratio | ★ $38.31 | $614.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $61.84 | $232.78 |
| 52 Week High | $92.55 | $385.22 |
| Indicator | ALC | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 37.76 | 40.54 |
| Support Level | $61.84 | $275.79 |
| Resistance Level | $81.92 | $314.18 |
| Average True Range (ATR) | 1.66 | 8.26 |
| MACD | -0.45 | -1.12 |
| Stochastic Oscillator | 30.65 | 9.10 |
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.